Kangstem Biotech Co. Ltd Net Assets
Kangstem Biotech Co. Ltd net assets. Based on the latest financial reports, Kangstem Biotech Co. Ltd (217730) has net assets worth ₩56.56 Billion KRW (≈ $38.33 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩68.42 Billion ≈ $46.37 Million USD) and total liabilities (₩11.86 Billion ≈ $8.04 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 217730 net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩56.56 Billion |
| % of Total Assets | 82.66% |
| Annual Growth Rate | 12.51% |
| 5-Year Change | 1.45% |
| 10-Year Change | 200.56% |
| Growth Volatility | 39.82 |
Net Assets of Kangstem Biotech Co. Ltd (2015–2025)
Net assets of Kangstem Biotech Co. Ltd from 2015 to 2025. This chart illustrates how Kangstem Biotech Co. Ltd's net assets have evolved over time, based on quarterly financial data. See Kangstem Biotech Co. Ltd (217730) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Kangstem Biotech Co. Ltd (2015–2025)
The table below shows the annual net assets of Kangstem Biotech Co. Ltd from 2015 to 2025. For live market cap and overall valuation, see Kangstem Biotech Co. Ltd stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩69.06 Billion ≈ $46.80 Million |
+59.93% |
| 2024-12-31 | ₩43.18 Billion ≈ $29.26 Million |
-3.00% |
| 2023-12-31 | ₩44.52 Billion ≈ $30.17 Million |
-5.80% |
| 2022-12-31 | ₩47.26 Billion ≈ $32.03 Million |
-30.57% |
| 2021-12-31 | ₩68.07 Billion ≈ $46.13 Million |
+31.87% |
| 2020-12-31 | ₩51.62 Billion ≈ $34.98 Million |
-27.01% |
| 2019-12-31 | ₩70.72 Billion ≈ $47.93 Million |
+48.29% |
| 2018-12-31 | ₩47.69 Billion ≈ $32.32 Million |
+103.17% |
| 2017-12-31 | ₩23.47 Billion ≈ $15.91 Million |
+2.16% |
| 2016-12-31 | ₩22.98 Billion ≈ $15.57 Million |
+8.19% |
| 2015-12-31 | ₩21.24 Billion ≈ $14.39 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Kangstem Biotech Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16126223597000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Kangstem Biotech Co. Ltd Net Assets Breakdown (December 2025)
Kangstem Biotech Co. Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩246.01 Billion | 358.38% |
| Total Equity | ₩68.65 Billion | 100.00% |
Kangstem Biotech Co. Ltd Competitors by Market Cap
The table below lists competitors of Kangstem Biotech Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Thai Sugar Terminal Public Company Limited
BK:TSTE
|
$121.87 Million |
|
RTX A/S
CO:RTX
|
$121.87 Million |
|
Jalles Machado S/A
SA:JALL3
|
$121.89 Million |
|
Fortune Information Systems Corp
TW:2468
|
$121.89 Million |
|
Unic Technology
TWO:5452
|
$121.74 Million |
|
PT Estee Gold Feet Tbk
JK:EURO
|
$121.72 Million |
|
Mostostal Zabrze - Holding SA
WAR:MSZ
|
$121.68 Million |
|
John Hancock Income Securities Closed Fund
NYSE:JHS
|
$121.59 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kangstem Biotech Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 43,182,021,410 to 68,645,131,900, a change of 25,463,110,490 (59.0%).
- Net loss of 10,482,078,490 reduced equity.
- New share issuances of 35,821,172,670 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-10.48 Billion | -15.27% |
| Share Issuances | ₩35.82 Billion | +52.18% |
| Other Changes | ₩124.02 Million | +0.18% |
| Total Change | ₩- | 58.97% |
Book Value vs Market Value Analysis
This analysis compares Kangstem Biotech Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.62x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.45x to 2.62x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1320.85 | ₩1911.00 | x |
| 2017-12-31 | ₩1180.15 | ₩1911.00 | x |
| 2018-12-31 | ₩2005.29 | ₩1911.00 | x |
| 2019-12-31 | ₩2970.21 | ₩1911.00 | x |
| 2020-12-31 | ₩1819.94 | ₩1911.00 | x |
| 2021-12-31 | ₩1794.32 | ₩1911.00 | x |
| 2022-12-31 | ₩1301.33 | ₩1911.00 | x |
| 2023-12-31 | ₩858.30 | ₩1911.00 | x |
| 2024-12-31 | ₩659.09 | ₩1911.00 | x |
| 2025-12-31 | ₩729.85 | ₩1911.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kangstem Biotech Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -15.27%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -293.41%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.19x
- Recent ROE (-15.27%) is above the historical average (-34.48%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -27.09% | -387.59% | 0.06x | 1.18x | ₩-7.88 Billion |
| 2016 | -36.12% | -984.85% | 0.02x | 2.06x | ₩-10.60 Billion |
| 2017 | -65.70% | -168.87% | 0.20x | 1.96x | ₩-17.77 Billion |
| 2018 | -28.62% | -148.91% | 0.13x | 1.53x | ₩-18.42 Billion |
| 2019 | -34.83% | -410.26% | 0.05x | 1.61x | ₩-31.71 Billion |
| 2020 | -35.78% | -202.14% | 0.11x | 1.60x | ₩-23.63 Billion |
| 2021 | -31.36% | -172.10% | 0.12x | 1.52x | ₩-28.16 Billion |
| 2022 | -40.99% | -124.14% | 0.20x | 1.63x | ₩-25.17 Billion |
| 2023 | -45.72% | -371.22% | 0.07x | 1.69x | ₩-26.75 Billion |
| 2024 | -17.76% | -99.01% | 0.14x | 1.30x | ₩-11.99 Billion |
| 2025 | -15.27% | -293.41% | 0.04x | 1.19x | ₩-17.35 Billion |
Industry Comparison
This section compares Kangstem Biotech Co. Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $287,302,015,827
- Average return on equity (ROE) among peers: -9.13%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kangstem Biotech Co. Ltd (217730) | ₩56.56 Billion | -27.09% | 0.21x | $121.81 Million |
| ORIENTBIO Inc. (002630) | $62.29 Billion | 1.41% | 1.19x | $94.35 Million |
| Green Cross (005250) | $895.76 Billion | 3.06% | 4.14x | $285.63 Million |
| Green Cross Holdings Preference Shares (005257) | $1.67 Trillion | 10.22% | 0.94x | $2.85 Million |
| Pharmicell (005690) | $82.42 Billion | -31.18% | 0.21x | $361.91 Million |
| GeneOne Life Science Inc (011000) | $24.06 Billion | -31.66% | 1.13x | $32.81 Million |
| HLB Co. Ltd (028300) | $46.46 Billion | 0.00% | 0.75x | $3.66 Billion |
| Mgenplus Co. Ltd. (032790) | $11.48 Billion | -51.58% | 1.56x | $19.35 Million |
| Daesung Microbiological Labs. Co. Ltd (036480) | $19.73 Billion | 2.26% | 0.29x | $13.93 Million |
| Seoulin Bioscience Co.Ltd (038070) | $43.14 Billion | 6.18% | 0.41x | $21.71 Million |
| Hyundai Bioscience Co. Ltd (048410) | $14.17 Billion | 0.00% | 1.15x | $342.04 Million |
About Kangstem Biotech Co. Ltd
Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn's disease. It also provides stem cell conditioned media, such a… Read more